CONNEQT Health has landed a significant Phase 2b clinical trial contract in the US, advancing its footprint in cardiovascular disease research with proprietary vascular assessment technology.
- New Phase 2b clinical trial contract awarded by US biopharmaceutical company
- Contract valued at approximately A$1.1 million over nine months
- Deployment of 30 SphygmoCor XCEL and 60 Oscar 2 ABPM systems across 30 US sites
- Services include equipment leasing, training, support, and data management
- Trial focuses on hypertension and serious cardiovascular diseases
Expanding Clinical Horizons
CONNEQT Health Limited (ASX, CQT) has announced a new milestone in its growth trajectory with the award of a Phase 2b clinical trial contract from a privately owned US biopharmaceutical company. This contract, valued at around A$1.1 million, marks a significant expansion of CONNEQT’s presence in the competitive US cardiovascular research market.
The Trial and Technology
Set to commence in the fourth quarter of 2025, the trial will span approximately nine months and involve 30 clinical sites across the United States. CONNEQT will supply its proprietary vascular assessment technology, including 30 SphygmoCor® XCEL systems and 60 Oscar 2 ambulatory blood pressure monitoring devices. Beyond equipment, the company will provide comprehensive setup, training, operational support, and data management services, ensuring the trial’s endpoints are measured with precision and reliability.
Strategic Significance
This contract underscores the growing confidence biopharmaceutical leaders have in CONNEQT’s non-invasive vascular biomarker technology. CEO Craig Cooper highlighted the importance of this partnership, noting it as a key step in broadening the company’s clinical and pharmaceutical collaborations. The trial’s focus on hypertension and cardiovascular disease aligns closely with CONNEQT’s mission to advance medical technology that improves vascular health and longevity.
Financial and Market Implications
Revenue from this contract will be recognised progressively over the trial’s duration, providing a steady income stream and enhancing CONNEQT’s financial visibility. The deal also positions the company well for potential follow-on contracts as the trial progresses and results emerge. While the identity of the US biopharmaceutical partner remains undisclosed, the scale and scope of this engagement signal strong market validation of CONNEQT’s technology platform.
Looking Ahead
As the trial kicks off, all eyes will be on CONNEQT’s ability to deliver on its technology promise and operational commitments. Success here could open doors to further clinical collaborations and cement the company’s role as a key player in cardiovascular disease research and treatment innovation.
Bottom Line?
CONNEQT’s US trial contract sets the stage for deeper clinical partnerships and revenue growth in a vital healthcare sector.
Questions in the middle?
- Which US biopharmaceutical company is behind the contract, and what are their pipeline ambitions?
- How will CONNEQT’s technology performance in this trial influence future adoption in cardiovascular studies?
- What are the potential commercial opportunities following successful trial completion?